Journal article
Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis
Abstract
BACKGROUND: The global incidence of myelodysplastic syndromes (MDS) has been estimated as 0.06 to 0.26/100,000. Since their introduction, hypomethylating agents have played a central role in the treatment of MDS, with heterogeneous real-world outcomes.
MATERIALS AND METHODS: We assessed and synthesized clinical outcomes of azacitidine (AZA) monotherapy in treatment-naïve patients with higher-risk MDS. A systematic literature review was …
Authors
Hasegawa K; Wei AH; Garcia-Manero G; Daver NG; Rajakumaraswamy N; Iqbal S; Chan RJ; Hu H; Tse P; Yan J
Journal
Clinical Lymphoma Myeloma & Leukemia, Vol. 23, No. 2, pp. 127–137
Publisher
Elsevier
Publication Date
February 2023
DOI
10.1016/j.clml.2022.11.002
ISSN
2152-2650